Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.

By P. Tricoci, Zhen Huang, C. Held, D. Moliterno, P. Armstrong, F. Van de Werf, Harvey D. White, P. Aylward, L. Wallentin, E. Chen and 32 more. New England Journal of Medicine, 2012

748 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Hematology

View Paper: https://www.semanticscholar.org/paper/0a81faf2b500952e939b9be313f93bf4b5c7dd21

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. Alejandro Rabinstein
2. M. Levi
3. R. Redberg
4. Nancy R. Cook
5. P. Ridker

In Hematology

1. H. Versteeg
2. Pieter H. Reitsma
3. J. Heemskerk
4. M. Levi

Citations in the corpus

• New fundamentals in hemostasis. (2013, background): “Markedly, recent clinical trials aiming to reduce platelet function with PAR1 antagonists are of miscellaneous success and even show increased (intercranial) bleeding (294).”
• 2018 ESC/EACTS Guidelines on myocardial revascularization. (2019, neutral): “The risk of periprocedural complications of PCI defined as MI or myocardial injury, as well as that of long-term ischaemia, remains higher in NSTE-ACS than in stable patients.(186,187) For ACS patients who have undergone PCI, revascularization procedures represent the most frequent, most costly, and”
• Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage (2016, background): “The only available PAR-1 inhibitor (vorapaxar) is contraindicated in patients with a history of stroke, TIA, or intracranial hemorrhage [390, 391].”